Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be approved in combination with ...

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025; Marks the ...

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in ...

A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized approach to precision medicine, as published in Frontiers in Science, could ...

A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

“The positive results from this confirmatory patient study represent an important step in the development of the Xolair® biosimilar candidate. We look forward to working with our partners to increase ...

The efficacy data of aficamten in obstructive HCM patients with mild symptoms from SEQUOIA-HCM were simultaneously published in The European Heart Journal. The Vice President and Head of Clinical ...

Novo Nordisk NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...